{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:44:05Z","timestamp":1780393445887,"version":"3.54.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013795","name":"Fujian Medical University","doi-asserted-by":"publisher","award":["2021QH1059"],"award-info":[{"award-number":["2021QH1059"]}],"id":[{"id":"10.13039\/501100013795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.clbc.2023.03.013","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T03:47:47Z","timestamp":1680234467000},"page":"508-518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression"],"prefix":"10.1016","volume":"23","author":[{"given":"Xiaoting","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhua","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-9663","authenticated-orcid":false,"given":"Pinfang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2023.03.013_bib0001","unstructured":"Breast cancer, version 4.2022, NCCN clinical practice guidelines in oncology. Available at: http:\/\/guide.medlive.cn\/guideline. Accessed: July 14, 2022."},{"issue":"1","key":"10.1016\/j.clbc.2023.03.013_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"npj Breast Cancer"},{"issue":"7","key":"10.1016\/j.clbc.2023.03.013_bib0003","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2023.03.013_bib0004","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/oncolo\/oyac107","article-title":"Clinical practices and institutional protocols on prophylaxis, monitoring, and management of selected adverse events associated with trastuzumab deruxtecan","volume":"27","author":"Bardia","year":"2022","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.clbc.2023.03.013_bib0005","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clbc.2023.03.013_bib0006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2023.03.013_bib0007","doi-asserted-by":"crossref","unstructured":"Wan XM, Peng L, Ma JA, Li YJ. Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from us and chinese perspectives. Cancer 2017:123:2634-2641.","DOI":"10.1002\/cncr.30666"},{"issue":"3","key":"10.1016\/j.clbc.2023.03.013_bib0008","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1634\/theoncologist.2018-0150","article-title":"Cost-effectiveness of osimertinib in treating newly diagnosed, advanced EGFR-mutation-positive non-small cell lung cancer","volume":"24","author":"Wu","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2023.03.013_bib0009","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jamaoncol.2018.7086","article-title":"First-line nivolumab plus ipilimumab vs sunitinib for metastatic renal cell carcinoma: a cost-effectiveness analysis","volume":"5","author":"Wan","year":"2019","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.clbc.2023.03.013_bib0010","unstructured":"National Bureau of Statistics of China. Annual data. 2022. Available at: http:\/\/www.stats.gov.cn\/english\/Statisticaldata\/AnnualData. Accessed: August 4, 2022."},{"issue":"7","key":"10.1016\/j.clbc.2023.03.013_bib0011","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1524-4733.2008.00394.x","article-title":"Health state utility scores for cancer-related anemia through societal and patient valuations","volume":"11","author":"Lloyd","year":"2008","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.clbc.2023.03.013_bib0012","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11136-016-1388-1","article-title":"Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial","volume":"26","author":"Shiroiwa","year":"2017","journal-title":"Qual Life Res"},{"issue":"6","key":"10.1016\/j.clbc.2023.03.013_bib0013","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","article-title":"Health state utilities for metastatic breast cancer","volume":"95","author":"Lloyd","year":"2006","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.clbc.2023.03.013_bib0014","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"10.1016\/j.clbc.2023.03.013_bib0015","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/13696998.2016.1269015","article-title":"Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer","volume":"20","author":"Gharaibeh","year":"2017","journal-title":"J Med Econ"},{"issue":"5","key":"10.1016\/j.clbc.2023.03.013_bib0016","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/COC.0000000000000671","article-title":"First-line treatment with atezolizumab plus nab-paclitaxel for advanced triple-negative breast cancer: a cost-effectiveness analysis","volume":"43","author":"Weng","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.03.013_bib0017","unstructured":"Drug Information Center. Drug information inquiry. 2022. Available at: https:\/\/db.yaozh.com\/yaopinzhongbiao. Accessed: August 9, 2022."},{"issue":"4","key":"10.1016\/j.clbc.2023.03.013_bib0018","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1016\/j.clbc.2021.01.019","article-title":"First-line treatment with ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive advanced breast cancer: a cost-effectiveness analysis","volume":"21","author":"Huang","year":"2021","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.clbc.2023.03.013_bib0019","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s40425-018-0440-9","article-title":"Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma","volume":"6","author":"Wu","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.clbc.2023.03.013_bib0020","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2165\/11314750-000000000-00000","article-title":"Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide","volume":"27","author":"Liubao","year":"2009","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.clbc.2023.03.013_bib0021","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.clbc.2015.04.001","article-title":"Economic evaluations of everolimus versus other hormonal therapies in the treatment of HR+\/HER2\u2212 advanced breast cancer from a US payer perspective","volume":"15","author":"Xie","year":"2015","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2023.03.013_bib0022","unstructured":"Exchange rate inquiry. Available at: http:\/\/www.exchangerates24.com. 2022. Accessed: August 9, 2022."},{"key":"10.1016\/j.clbc.2023.03.013_bib0023","unstructured":"Bureau of Labor Statistics. 2022. Available at: https:\/\/www.usa.gov\/federal-agencies\/bureau-of-labor-statistics. Accessed: August 9, 2022."},{"key":"10.1016\/j.clbc.2023.03.013_bib0024","unstructured":"China Guidelines for Pharmacoeconomic Evaluations (2020 Chinese-English Version). 2020. Available at: https:\/\/max.book118.com\/html\/2020\/0929\/8000037103003002.shtm. Accessed: September 19, 2022."},{"key":"10.1016\/j.clbc.2023.03.013_bib0025","unstructured":"Institute for Clinical and Economic Review, Overview of the ICER value framework and proposals for an update for 2017. 2017. Available at: http:\/\/icer-review.org\/wp-content\/uploads\/2016\/02\/ICER-VAF-Update-Proposals-020117.pdf. Accessed: September 19, 2022."},{"issue":"20","key":"10.1016\/j.clbc.2023.03.013_bib0026","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1002\/cncr.32368","article-title":"First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non\u2013small cell lung cancer: a United States\u2013based cost-effectiveness analysis","volume":"125","author":"Wan","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clbc.2023.03.013_bib0027","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s12913-018-3185-8","article-title":"Revisiting out-of-pocket requirements: trends in spending, financial access barriers, and policy in ten high-income countries","volume":"18","author":"Rice","year":"2018","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.clbc.2023.03.013_bib0028","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1200\/JCO.2015.62.2860","article-title":"Global health equity: cancer care outcome disparities in high-, middle-, and low-income countries","volume":"34","author":"de Souza","year":"2016","journal-title":"JCO"},{"issue":"9","key":"10.1016\/j.clbc.2023.03.013_bib0029","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2015.64.6620","article-title":"Financial insolvency as a risk factor for early mortality among patients with cancer","volume":"34","author":"Ramsey","year":"2016","journal-title":"JCO"},{"issue":"10","key":"10.1016\/j.clbc.2023.03.013_bib0030","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1016\/S2352-3026(15)00151-9","article-title":"Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study","volume":"2","author":"Huntington","year":"2015","journal-title":"Lancet Haematology"},{"issue":"1","key":"10.1016\/j.clbc.2023.03.013_bib0031","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1377\/hlthaff.2015.0830","article-title":"For working-age cancer survivors, medical debt and bankruptcy create financial hardships","volume":"35","author":"Banegas","year":"2016","journal-title":"Health Affairs"},{"issue":"1","key":"10.1016\/j.clbc.2023.03.013_bib0032","doi-asserted-by":"crossref","first-page":"93","DOI":"10.21037\/hbsn-2021-3","article-title":"An overview of the Chinese healthcare system","volume":"10","author":"Yi","year":"2021","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.clbc.2023.03.013_bib0033","unstructured":"Chinese Healthcare- A Rural Problem. 2015. Available at: https:\/\/econ274.academic.wlu.edu\/2015\/10\/chinese-healthcare-a-rural-problem\/. Accessed: July 10, 2022."},{"issue":"7","key":"10.1016\/j.clbc.2023.03.013_bib0034","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/S1470-2045(13)70567-9","article-title":"Breast cancer in China","volume":"15","author":"Fan","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2023.03.013_bib0035","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(14)70029-4","article-title":"Challenges to effective cancer control in China, India, and Russia","volume":"15","author":"Goss","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10204","key":"10.1016\/j.clbc.2023.03.013_bib0036","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S0140-6736(19)32136-1","article-title":"10 years of health-care reform in China: progress and gaps in Universal Health Coverage","volume":"394","author":"Yip","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2023.03.013_bib0037","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/oncolo\/oyac258","article-title":"The fragile economics of cancer treatments","volume":"28","year":"2023","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.clbc.2023.03.013_bib0038","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S1470-2045(11)70141-3","article-title":"Delivering affordable cancer care in high-income countries","volume":"12","author":"Sullivan","year":"2011","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2023.03.013_bib0039","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.19.01455","article-title":"NSABP B-47\/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2+","volume":"38","author":"Fehrenbacher","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.clbc.2023.03.013_bib0040","unstructured":"National Development and Reform Commission. Abolishment of government (guided) pricing for the majority of drugs and push to the drug pricing reform [in Chinese]. 2022. Available at: https:\/\/www.ndrc.gov.cn\/xxgk\/zcfb\/tz\/201505\/t20150505_963815.html?code=&state=123. Accessed: October 21, 2022."},{"key":"10.1016\/j.clbc.2023.03.013_bib0041","unstructured":"State Council of the People's Republic of China. China to cut prices of expensive patent drugs. [in Chinese]. 2022. Available at: http:\/\/english.gov.cn\/news\/top_new\/2016\/05\/20\/content_281475353689066.html. Accessed: October 21, 2022."},{"issue":"10","key":"10.1016\/j.clbc.2023.03.013_bib0042","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1007\/s12325-022-02273-4","article-title":"Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer in the USA","volume":"39","author":"Wang","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.clbc.2023.03.013_bib0043","article-title":"Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer","volume":"13","author":"Yang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.clbc.2023.03.013_bib0044","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40273-016-0386-z","article-title":"Trastuzumab emtansine for treating HER2-positive, unresectable, locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane: an evidence review group perspective of a NICE single technology appraisal","volume":"34","author":"Squires","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clbc.2023.03.013_bib0045","article-title":"Economic evaluation of sacituzumab govitecan for the treatment of metastatic triple-negative breast cancer in China and the US","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.clbc.2023.03.013_bib0046","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40261-021-01035-4","article-title":"Cost-effectiveness analysis of trastuzumab emtansine as second-line therapy for HER2-positive breast cancer in China","volume":"41","author":"Zhang","year":"2021","journal-title":"Clin Drug Investig"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820923000824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820923000824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:23:58Z","timestamp":1761513838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820923000824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1526820923000824"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2023.03.013","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2023.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}